These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown. Chentoufi AA; Kritzer E; Yu DM; Nesburn AB; Benmohamed L Clin Dev Immunol; 2012; 2012():187585. PubMed ID: 22548113 [TBL] [Abstract][Full Text] [Related]
14. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response. Bettahi I; Zhang X; Afifi RE; BenMohamed L Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765 [TBL] [Abstract][Full Text] [Related]
15. Genital herpes vaccines--cause for cautious optimism. Haddow LJ; Mindel A Sex Health; 2006 Mar; 3(1):1-4. PubMed ID: 16607967 [TBL] [Abstract][Full Text] [Related]
16. Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine. Samandary S; Kridane-Miledi H; Sandoval JS; Choudhury Z; Langa-Vives F; Spencer D; Chentoufi AA; Lemonnier FA; BenMohamed L Hum Immunol; 2014 Aug; 75(8):715-29. PubMed ID: 24798939 [TBL] [Abstract][Full Text] [Related]
17. A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections. Chiuppesi F; Vannucci L; De Luca A; Lai M; Matteoli B; Freer G; Manservigi R; Ceccherini-Nelli L; Maggi F; Bendinelli M; Pistello M J Virol; 2012 Jun; 86(12):6563-74. PubMed ID: 22491465 [TBL] [Abstract][Full Text] [Related]